Cochrane Evidence Synthesis and Methods ►

Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To determine the benefits and harms of dose reduction or discontinuation of biologic disease-modifying anti-rheumatic drugs or targeted synthetic disease-modifying anti-rheumatic drugs in adults with psoriatic arthritis who are in remission or a low disease activity state.

This is a protocol.

Published:

16 December 2024

Authors:

Ramsay H, Johnston RV, Cyril S, Glennon V, Grobler L, Burgess DM, McKenzie BJ, Whittle SL, Buchbinder R

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Ramsay H, Johnston RV, Cyril S, Glennon V, Grobler L, Burgess DM, McKenzie BJ, Whittle SL, Buchbinder R. Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity (Protocol). Cochrane Database of Systematic Reviews 2024, Issue 12. Art. No.: CD015880. DOI: 10.1002/14651858.CD015880.